Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PS-341 plus Docetaxel in Advanced Androgen-Independent Prostate Cancer
NCT00064610Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Dec 2002
- Primary completion
- Dec 2004
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in prostate cancer (PCa), sponsored by Millennium Pharmaceuticals. Started Dec 2002; status: completed.
02
Drugs
bortezomib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00064610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00064610.